Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kiniksa Pharmaceuticals Ltd (KNSA)
Kiniksa Pharmaceuticals Ltd (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,182,382
  • Shares Outstanding, K 70,338
  • Annual Sales, $ 220,180 K
  • Annual Income, $ 183,360 K
  • 60-Month Beta -0.16
  • Price/Sales 5.17
  • Price/Cash Flow 5.94
  • Price/Book 2.75
Trade KNSA with:

Options Overview Details

View History
  • Implied Volatility 76.31% ( -13.98%)
  • Historical Volatility 44.63%
  • IV Percentile 85%
  • IV Rank 58.25%
  • IV High 116.63% on 02/15/23
  • IV Low 20.06% on 10/16/23
  • Put/Call Vol Ratio 0.20
  • Today's Volume 12
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 2,671
  • Open Int (30-Day) 2,729

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate 0.00
  • Low Estimate -0.23
  • Prior Year 0.06
  • Growth Rate Est. (year over year) -350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.12 +19.05%
on 11/10/23
16.83 -0.12%
on 12/01/23
+1.67 (+11.03%)
since 11/01/23
3-Month
14.12 +19.05%
on 11/10/23
18.00 -6.61%
on 09/19/23
-0.95 (-5.35%)
since 09/01/23
52-Week
10.29 +63.36%
on 04/10/23
20.65 -18.60%
on 07/26/23
-0.24 (-1.41%)
since 12/01/22

Most Recent Stories

More News
3 Pharma Stocks to Watch for Value in September

The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa...

CPRX : 14.82 (+2.70%)
KNSA : 16.81 (+3.96%)
OPK : 1.5300 (+4.79%)
PFE : 28.91 (-5.12%)
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar

Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...

HALO : 39.69 (+2.80%)
KNSA : 16.81 (+3.96%)
ACAD : 22.60 (+1.44%)
HRMY : 30.48 (+4.89%)
AMPH : 57.92 (+2.84%)
INCY : 54.02 (-0.59%)
AGEN : 0.7827 (+0.72%)
NVS : 98.13 (+0.23%)
PFE : 28.91 (-5.12%)
SGEN : 212.72 (-0.23%)
MRK : 103.46 (+0.96%)
RXDX : 199.92 (+0.09%)
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday

The company reported a big jump in revenue and updated guidance.

KNSA : 16.81 (+3.96%)
3 Pharma Stocks to Buy for a Smart Investment

With the rise of chronic diseases and technological advancements, the pharma market looks poised for substantial expansion. So, fundamentally strong pharma stocks Kiniksa Pharmaceuticals (KNSA), Collegium...

COLL : 25.60 (-0.12%)
KNSA : 16.81 (+3.96%)
WVE : 5.51 (+3.77%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

KNSA : 16.81 (+3.96%)
TRVN : 0.5850 (+0.55%)
After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

KNSA : 16.81 (+3.96%)
Centene (CNC) Expands Evolent Partnership to Boost Quality

Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.

AMPH : 57.92 (+2.84%)
CNC : 74.88 (+1.63%)
EVH : 28.93 (+4.06%)
KNSA : 16.81 (+3.96%)
HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza

HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.

AMPH : 57.92 (+2.84%)
HCA : 252.36 (+0.75%)
KNSA : 16.81 (+3.96%)
PNTG : 13.67 (-0.36%)
Select Medical (SEM) Forays Into Indiana With Lutheran Health JV

Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.

AMPH : 57.92 (+2.84%)
SEM : 23.45 (+3.76%)
KNSA : 16.81 (+3.96%)
PNTG : 13.67 (-0.36%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

KNSA : 16.81 (+3.96%)
ABSI : 1.7400 (+4.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 17.87
2nd Resistance Point 17.35
1st Resistance Point 17.08
Last Price 16.81
1st Support Level 16.29
2nd Support Level 15.77
3rd Support Level 15.50

See More

52-Week High 20.65
Last Price 16.81
Fibonacci 61.8% 16.69
Fibonacci 50% 15.47
Fibonacci 38.2% 14.25
52-Week Low 10.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar